What Is Ozempic Gastroparesis? A Plain-Language Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

If you or someone you know has been taking Ozempic and is experiencing persistent nausea, vomiting, or a feeling of fullness after eating small amounts, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have long recognized that certain medications can slow gastric motility, and recent reports have linked GLP-1 receptor agonists like Ozempic to this effect. This page explains the condition in plain language, covering symptoms, risk factors, and what the science says.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking GLP-1 receptor agonists like Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 agonists slow gastric emptying, which is part of their therapeutic action for glycemic control, but this effect can become pathological in some patients, leading to symptomatic gastroparesis. The reported gastrointestinal adverse reactions with Ozempic include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the spectrum of gastrointestinal effects suggests a plausible link, as delayed gastric emptying is a known consequence of GLP-1 receptor activation.

Adequacy of Warnings and Legal Implications

Regarding the adequacy of warnings, the Ozempic prescribing information includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a distinct adverse reaction. The gastrointestinal adverse reactions are described in terms of nausea, vomiting, diarrhea, and other symptoms, but the term 'gastroparesis' is absent. This omission may be relevant for patients who develop severe or persistent symptoms consistent with gastroparesis after starting Ozempic. The lack of a specific warning could affect the adequacy of informed consent and the ability of patients to recognize and report symptoms early. For patients in New Jersey considering a settlement related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For product liability claims involving prescription drugs, the discovery rule applies, meaning the clock starts when the plaintiff knew or should have known that the drug caused the harm. Given that gastroparesis symptoms may develop gradually and be initially attributed to other causes, the timeline between exposure to Ozempic and documented harm is important. Patients who began Ozempic and later developed persistent nausea, vomiting, or abdominal bloating should document the onset of symptoms and any medical evaluations confirming delayed gastric emptying. The time between starting Ozempic and the diagnosis of gastroparesis can vary from weeks to months, and this interval will influence when the statute of limitations begins.

Settlement Considerations and Evidence Requirements

Settlement-related considerations for affected patients include the need to establish a causal link between Ozempic and gastroparesis, which may require expert testimony on the mechanistic pathways and clinical presentation. The evidence from clinical trials shows a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, but individual cases of gastroparesis may need to be distinguished from other causes. Patients should also consider the strength of the warning provided by the manufacturer. Since the label does not specifically mention gastroparesis, plaintiffs may argue that the warnings were inadequate. However, the label does list gastrointestinal adverse reactions that overlap with gastroparesis symptoms, which could complicate claims of insufficient warning. In summary, the medical narrative linking Ozempic to gastroparesis is supported by the drug's known effects on gastric motility and the higher rate of gastrointestinal adverse reactions in clinical trials. The absence of a specific gastroparesis warning in the label may be a point of contention in legal claims. For New Jersey patients, the statute of limitations requires prompt action after discovery of the injury, and the timeline between exposure and harm must be carefully documented. Settlement considerations will depend on the strength of the causal evidence and the adequacy of warnings provided to patients. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For product liability claims involving prescription drugs, the discovery rule applies, meaning the clock starts when the plaintiff knew or should have known that the drug caused the harm. Given that gastroparesis symptoms may develop gradually, it is crucial to document the onset of symptoms and the date of diagnosis to determine the filing deadline.

Does the Ozempic label specifically warn about gastroparesis?

No, the Ozempic prescribing information does not specifically warn about gastroparesis as a distinct adverse reaction. While it lists gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, the term 'gastroparesis' is absent. This omission may be relevant for patients who develop severe or persistent symptoms consistent with gastroparesis after starting Ozempic, as it could affect the adequacy of informed consent and the ability to recognize and report symptoms early.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.